Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disease-Modifying Treatments for Transthyretin Amyloidosis.

Journal of cardiovascular pharmacology - 1 Nov 2021

Tushak Zackary J, Cox Stephen Zach, Cei Laura F, Gwathmey Kelly G, Shah Keyur B

Abstract excerpt

ABSTRACT: The transthyretin (TTR) amyloidoses result from misfolding of the protein leading to fibril formation and aggregation as amyloid deposits in predominantly the cardiovascular and nervous systems. Cardiac involvement can manifest as heart failure, arrhythmias, and valvular disease. Neurologic involvement can cause sensorimotor polyneuropathies, mononeuropathies, and dysautonomia. Previously, treatment has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid
Share to Amyloid Neuropathies, Familial
Share to Cardiomyopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiovascular Agents

Share to Genetic Therapy

Share to Myocytes, Cardiac

Share to Prealbumin

Share to Protein Stability

Source

Identifiers

PMID: 34321398
DOI: 10.1097/FJC.0000000000001115

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disease-Modifying Treatments for Transthyretin Amyloidosis.PMID 34321398Read ↗

Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.Semantic proximity Read ↗

Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies.Semantic proximity Read ↗

Updates on hereditary transthyretin amyloidosis polyneuropathy.Semantic proximity Read ↗

Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy ManagementSemantic proximity Read ↗

Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.Semantic proximity Read ↗

The transthyretin amyloidoses: advances in therapySemantic proximity Read ↗

Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin AmyloidosisSemantic proximity Read ↗

Transthyretin: Its function and amyloid formation.Semantic proximity Read ↗

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated ReviewSemantic proximity Read ↗

Hereditary transthyretin amyloidosis overview.Semantic proximity Read ↗

Guideline of transthyretin-related hereditary amyloidosis for cliniciansSemantic proximity Read ↗

Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.